We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.

We developed a biomimetic triple-antibody-immobilized magnetic fucoidan nanomedicine as a multifunctional artificial antigen presenting cell, which possessed the ability to not only inhibit immune checkpoint but activate tumor infiltrated T cells. of Bridging sites with tunable density on the nanoplatform was designed, allowing the antibodies to be well-distributed on the surface for mimicking immune cells. In contrast to the complex cell expansion process using microbeads in adaptive cell therapy, the nanoplatform can be i.v. administrated to cut the course of therapy from several weeks to days. With the development of the platform technology, an artificial immune system family can be built to pave the way for personalized immunotherapy.

Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.

In the current of study, cell subsets, cell proportionsthe immune function of tumors-infiltrating leukocytes were used to indicate the features of tumor immune microenvironment in non-small cell lung cancers (NSCLCs) with different type of EGFR genetic alteration.